Ocular Therapeutix (OCUL) Operating Leases: 2019-2025

Historic Operating Leases for Ocular Therapeutix (OCUL) over the last 7 years, with Sep 2025 value amounting to $3.6 million.

  • Ocular Therapeutix's Operating Leases fell 35.10% to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.6 million, marking a year-over-year decrease of 35.10%. This contributed to the annual value of $5.3 million for FY2024, which is 22.29% down from last year.
  • According to the latest figures from Q3 2025, Ocular Therapeutix's Operating Leases is $3.6 million, which was down 17.67% from $4.4 million recorded in Q2 2025.
  • In the past 5 years, Ocular Therapeutix's Operating Leases ranged from a high of $8.7 million in Q4 2022 and a low of $3.6 million during Q3 2025.
  • Over the past 3 years, Ocular Therapeutix's median Operating Leases value was $6.1 million (recorded in 2024), while the average stood at $6.0 million.
  • In the last 5 years, Ocular Therapeutix's Operating Leases skyrocketed by 57.29% in 2023 and then slumped by 35.10% in 2025.
  • Ocular Therapeutix's Operating Leases (Quarterly) stood at $5.9 million in 2021, then spiked by 46.49% to $8.7 million in 2022, then decreased by 20.74% to $6.9 million in 2023, then dropped by 22.29% to $5.3 million in 2024, then crashed by 35.10% to $3.6 million in 2025.
  • Its Operating Leases stands at $3.6 million for Q3 2025, versus $4.4 million for Q2 2025 and $4.9 million for Q1 2025.